"Erectile dysfunction is very often associated with high cholesterol. Many physicians are not treating ED, a life-changing condition", said Mr. Ian Eardley, consultant urologist and honorary senior lecturer at St. James University Hospital, Leeds. "This study provides further support that Levitra® can successfully treat ED, even in men with a serious underlying condition like high cholesterol. Nearly 70% of men with ED have an underlying condition such as high blood pressure, diabetes or high cholesterol levels. The accumulating evidence shows that Levitra® is a potent treatment for ED in men with underlying conditions", he emphasized at the EAU congress in Milan.
ED and testosterone deficiency often share the same underlying conditions such as dyslipidemia, cardiovascular disease and obesity. The presence of ED should automatically trigger tests to establish testosterone levels, as testosterone deficiency is a significant detriment to quality of life.
Also presented at the EAU in Milan, new data from the European Testogel®-Study, which showed that testosterone therapy with Testogel® may improve cardiovascular and metabolic conditions and quality of life in men with low testosterone (hypogonadism). In the international, multicenter, randomized, double-blind, placebo-controlled study, 362 men aged 50-80 with late on-set hypogandism (LOH), i.e. testosterone deficiency associated with aging, were randomized to receive Testogel® or placebo for 6 months, followed by a 12-month open-label phase during which all patients received Testogel.
Over the first six months, Testogel® use was associated with significant improvements in cardiovascular and metabolic profiles, as well as quality-of-life scores as measured by the aging male symptom scale (AMS) compared to placebo. Once all study participants were using Testogel® the difference between the two groups narrowed considerably to a point where there was little difference between the study participants' scores on the total AMS and sexual subscale, or between their cardiovascular and metabolic profiles. The study concluded that testosterone therapy may offer benefits for men's overall health and be associated with improvements in cardiovascular and metabolic profiles and quality of life in men with LOH.
About Bayer HealthCare
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma and as Bayer HealthCare Pharmaceuticals in the US and Canada. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. http://www.bayerhealthcare.com
About Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. http://www.bayerscheringpharma.de
 Miner M. Vardenafil Efficacy and Safety in Men With Erectile Dysfunction and Dyslipidemia: A 12-Week, Randomized, Placebo-Controlled Trial. Abstract presented at Sexual Medicine Society of North America Fall Meeting, December 2007, Chicago, USA.
 Miner M, and Billups KL. Erectile dysfunction and dyslipidemia: Relevance and role of phosphodiesterase type-5 inhibitors and statins. J Sex Med 2008;5(suppl 1):4-41
 Bouloux PM et al. Testosterone therapy in men with late-onset hypogonadism: the benefits for menâs overall health. Data presented at the Bayer Schering Pharma Symposium at the 23rd annual congress of the EAU, Milan, Italy, March 2008.